Biogen-Icahn showdown goes to a vote

Biogen Idec's proxy fight nears its culmination. Shareholders meet today to vote on a slate of directors named by activist investor Carl Icahn, who has called on the board to consider splitting the biotech giant in two. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.